CN101534844B - 液体硫属化物的组合物及其制备和使用方法 - Google Patents

液体硫属化物的组合物及其制备和使用方法 Download PDF

Info

Publication number
CN101534844B
CN101534844B CN200780041157.7A CN200780041157A CN101534844B CN 101534844 B CN101534844 B CN 101534844B CN 200780041157 A CN200780041157 A CN 200780041157A CN 101534844 B CN101534844 B CN 101534844B
Authority
CN
China
Prior art keywords
compositions
composition
scope
sulfide
liquid medicine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200780041157.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN101534844A (zh
Inventor
K·J·托马塞利
P·A·希尔
T·L·德克韦特
E·温特纳
C·萨博
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fred Hutchinson Cancer Center
Original Assignee
Fred Hutchinson Cancer Research Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fred Hutchinson Cancer Research Center filed Critical Fred Hutchinson Cancer Research Center
Publication of CN101534844A publication Critical patent/CN101534844A/zh
Application granted granted Critical
Publication of CN101534844B publication Critical patent/CN101534844B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
CN200780041157.7A 2006-10-05 2007-10-05 液体硫属化物的组合物及其制备和使用方法 Expired - Fee Related CN101534844B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US84990006P 2006-10-05 2006-10-05
US60/849,900 2006-10-05
US89672707P 2007-03-23 2007-03-23
US60/896,727 2007-03-23
PCT/US2007/080613 WO2008043081A2 (en) 2006-10-05 2007-10-05 Liquid chalcogenide compositions and methods of manufacturing and using the same

Publications (2)

Publication Number Publication Date
CN101534844A CN101534844A (zh) 2009-09-16
CN101534844B true CN101534844B (zh) 2014-04-23

Family

ID=39149128

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200780041157.7A Expired - Fee Related CN101534844B (zh) 2006-10-05 2007-10-05 液体硫属化物的组合物及其制备和使用方法

Country Status (13)

Country Link
US (1) US20080187604A1 (es)
EP (1) EP2068893A2 (es)
JP (1) JP5303465B2 (es)
KR (2) KR20150042291A (es)
CN (1) CN101534844B (es)
AU (1) AU2007303050B2 (es)
BR (1) BRPI0719539A2 (es)
CA (1) CA2664341C (es)
HK (1) HK1132905A1 (es)
IL (1) IL197945A (es)
MX (1) MX2009003741A (es)
NZ (1) NZ575671A (es)
WO (1) WO2008043081A2 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1879599T3 (pl) * 2005-04-20 2014-03-31 Hutchinson Fred Cancer Res Sposoby, kompozycje i wyroby do zwiększania przeżywalności komórek, tkanek, narządów i organizmów
WO2008079993A2 (en) * 2006-12-22 2008-07-03 Ikaria, Inc. Combinations of nitric oxide and sulfide and methods of use and manufacture thereof
EP2155213A1 (en) * 2007-06-15 2010-02-24 Ikaria, Inc. Compositions comprising sulfide alone or in combination with nitric oxide and their use to
EP2170356A1 (en) * 2007-06-25 2010-04-07 Fred Hutchinson Cancer Research Center Methods and compositions regarding polychalcogenide compositions
US20100183748A1 (en) 2009-01-21 2010-07-22 Ikaria, Inc. Methods for Treating or Preventing Radiocontrast Agent Induced Kidney Injury
US20100198338A1 (en) * 2009-01-30 2010-08-05 Medtronic Vascular, Inc., A Delaware Corporation Hydrogen Sulfide Donating Polymers
US8541396B2 (en) 2009-04-24 2013-09-24 National University Of Singapore Morpholin-4-ium 4 methoxyphenyl (morpholino) phosphinodithioate (GYY4137) as a novel vasodilator agent
WO2011079222A2 (en) 2009-12-23 2011-06-30 Boston Scientific Scimed, Inc. Less traumatic method of delivery of mesh-based devices into human body
US8182830B2 (en) * 2010-01-05 2012-05-22 Medtronic Vascular, Inc. Hydrogen sulfide generating polymers
EP2745102B1 (en) * 2011-08-19 2020-10-07 Northeastern University Chemical sensor based on highly organized single walled carbon nanotube networks
IN2014MN02391A (es) * 2012-06-13 2015-08-21 Hutchinson Fred Cancer Res
TW201420130A (zh) * 2012-09-26 2014-06-01 Neochemir Inc 溶解有二氧化碳之液狀藥劑及其投藥方法
EP2938187B1 (en) * 2012-12-31 2017-09-27 Somahlution, LLC Solution for preserving vascular conduits
JP2014201580A (ja) * 2013-04-10 2014-10-27 株式会社昭和冷凍プラント 窒素水を用いた移植臓器の保存用又は洗浄用の処理液及びその調製方法
US10201570B2 (en) 2014-02-10 2019-02-12 Fred Hutchinson Cancer Research Center Halogen treatment of heart attack and ischemic injury
CN107809996A (zh) * 2015-04-29 2018-03-16 Bsn医疗有限公司 一氧化氮产生的多步骤方法
CN106539818A (zh) * 2015-09-20 2017-03-29 复旦大学 硫化氢及其供体硫氢化钠在制备促造血药物中的用途
CN105964217B (zh) * 2016-06-17 2018-10-12 中国科学院城市环境研究所 一种磁性KMS-1/Fe3O4复合材料的制备方法及其用于去除环丙沙星
EP3299021A1 (en) * 2016-09-21 2018-03-28 Universitätsklinikum Jena Thiosulfate for treating hepatic ischemia/reperfusion injury
MX2019009384A (es) * 2017-02-09 2019-12-11 Noxsano Inc Composiciones generadoras de gastrotransmisores electroquimicos y sus metodos de uso y apositos y sistemas de tratamiento que los incorporan.
US11462358B2 (en) 2017-08-18 2022-10-04 Northeastern University Method of tetratenite production and system therefor
JP7138702B2 (ja) 2017-09-22 2022-09-16 ベクトン・ディキンソン・アンド・カンパニー カテーテルロック溶液としての使用のための４％クエン酸三ナトリウム溶液
US20220105126A1 (en) * 2020-10-02 2022-04-07 Craig Mercer Boulris Composition for preventing and treating microbial disease
US11679119B2 (en) 2021-09-24 2023-06-20 MAIA Pharmaceuticals, Inc. Bortezomib compositions
CN115040648B (zh) * 2022-06-02 2023-07-28 中山大学 一种基于硫化氢促进钙超载协同光热特异性治疗肿瘤的纳米粒及其制备方法
CN116804630B (zh) * 2023-08-03 2024-03-05 中拓生物有限公司 一种血清同型半胱氨酸测定试剂盒

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006113914A2 (en) * 2005-04-20 2006-10-26 Fred Hutchinson Cancer Research Center Methods, compositions and articles of manufacture for enhancing survivability of cells, tissues, organs, and organisms
WO2006119258A3 (en) * 2005-04-29 2007-03-29 Univ Houston Use of hydrogen sulfide in the treatment of eye diseases
WO2007124447A2 (en) * 2006-04-20 2007-11-01 Fred Hutchinson Cancer Research Center Use of chalcogenides for treating shock and other adverse conditions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5364555A (en) 1991-04-30 1994-11-15 Advanced Oxygen Technologies, Inc. Polymer compositions containing salicylic acid chelates as oxygen scavengers
US6458758B1 (en) 1993-08-16 2002-10-01 Synzyme Technologies, Inc. Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
JP2001507696A (ja) 1996-12-31 2001-06-12 アンチオキシダント ファーマシューティカルズ コーポレーション グルタチオンの医薬製剤およびその投与方法
EP1684579A1 (en) 2003-10-22 2006-08-02 Fred Hutchinson Cancer Research Center Methods, compositions and devices for inducing stasis in cells, tissues, organs, and organisms
US20050106214A1 (en) 2003-11-14 2005-05-19 Guohua Chen Excipients in drug delivery vehicles

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006113914A2 (en) * 2005-04-20 2006-10-26 Fred Hutchinson Cancer Research Center Methods, compositions and articles of manufacture for enhancing survivability of cells, tissues, organs, and organisms
WO2006119258A3 (en) * 2005-04-29 2007-03-29 Univ Houston Use of hydrogen sulfide in the treatment of eye diseases
WO2007124447A2 (en) * 2006-04-20 2007-11-01 Fred Hutchinson Cancer Research Center Use of chalcogenides for treating shock and other adverse conditions

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
《"H2S induced hypometabolism in mice is missing in sedated sheep》;HAOUZI PHILIPPE ET AL:;《 RESPIRATORY PHYSIOLOG NEUROBIOLOGY》;20080131;109-115页 *
《"H2S induces a suspended animation-like state in mice;BLACKSTONE ERIC ET AL;《 SCIENCE》;20050430;518页 *
《"Sulfide consumption by mussel gil mitochondria is not strictly tied to oxygen reduction measurements using a novel polarographic sulfide senso》;KRAUS DAVID W ET AL;《JOURNAL OF EXPERIMENTAL BIOLOGY》;20041030;3670页第1栏6-18行 *
BLACKSTONE ERIC ET AL.《"H2S induces a suspended animation-like state in mice.《 SCIENCE》.2005,
HAOUZI PHILIPPE ET AL:.《"H2S induced hypometabolism in mice is missing in sedated sheep》.《 RESPIRATORY PHYSIOLOG NEUROBIOLOGY》.2008,
KRAUS DAVID W ET AL.《"Sulfide consumption by mussel gil mitochondria is not strictly tied to oxygen reduction measurements using a novel polarographic sulfide senso》.《JOURNAL OF EXPERIMENTAL BIOLOGY》.2004,3667-3679.

Also Published As

Publication number Publication date
CA2664341A1 (en) 2008-04-10
AU2007303050A1 (en) 2008-04-10
AU2007303050B2 (en) 2013-11-07
BRPI0719539A2 (pt) 2014-01-14
EP2068893A2 (en) 2009-06-17
MX2009003741A (es) 2009-07-10
HK1132905A1 (en) 2010-03-12
WO2008043081A3 (en) 2008-05-29
CA2664341C (en) 2018-11-06
CN101534844A (zh) 2009-09-16
US20080187604A1 (en) 2008-08-07
IL197945A0 (en) 2009-12-24
NZ575671A (en) 2011-04-29
KR20150042291A (ko) 2015-04-20
WO2008043081A2 (en) 2008-04-10
KR20090086210A (ko) 2009-08-11
KR101538727B1 (ko) 2015-07-22
JP2010505879A (ja) 2010-02-25
IL197945A (en) 2016-12-29
JP5303465B2 (ja) 2013-10-02

Similar Documents

Publication Publication Date Title
CN101534844B (zh) 液体硫属化物的组合物及其制备和使用方法
US8226986B2 (en) Liquid chalcogenide compositions and methods of manufacturing and using the same
JP6573620B2 (ja) 心臓発作及び虚血損傷のハロゲン治療
ES2242131T3 (es) Utilizacion de acido r,s (+/-)alfa-lipoico, acido r-(+)-alfa-lipoico o acido s-(-)-alfa-lipoico en forma reducida u oxidada para el tratamiento de trastornos auditivos.
CN106456538A (zh) 液体药物组合物
HRP20020636A2 (en) Pharmaceutical composition comprising pemetrexed with monothioglycerol l-cystein or thioglycolic acid
Swami et al. Accidental intraoral injection of formalin during extraction: case report
CN106031710A (zh) 一种富马酸氟呐普拉赞的注射剂及其制备方法
KR20150021509A (ko) 칼코게나이드를 포함하는 조성물 및 관련 방법
CN105769756B (zh) 一种富马酸西他沙星注射剂及其制备方法
EP1004321B1 (en) Stable radioactive medecine
US20240033215A1 (en) Injectable formulation with enhanced stability containing dexibuprofen and arginin and their medicine vessel for injection
RU2817970C1 (ru) Лиофилизат на основе лигандов к простат-специфическому мембранному антигену (ПСМА) для приготовления радиофармацевтической композиции в форме раствора для инъекций для лечения рака предстательной железы, радиофармацевтическая композиция на ее основе для лечения рака предстательной железы и способ приготовления радиофармацевтической композиции
TWI524843B (zh) 保存血管導管之溶液
Nagyova et al. Inhibition of active sodium absorption leads to a net liquid secretion into in vivo rabbit lung at two levels of alveolar hypoxia
WO2008075379A1 (en) Novel formulation for enhanced delivery of diagnostic agents to tumor tissues
Whitaker Chloroform anaesthesia
Staubus Fundamentals of saturation kinetics--application to iopanic acid in the dog
UA50247U (uk) Препарат для лікування метаболічного ацидозу
BRPI1107224A2 (pt) soluÇço para conservaÇço de orgços, processo de fabricaÇço e modo de preparo
UA18403U (en) Hartman solution for infusions

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1132905

Country of ref document: HK

ASS Succession or assignment of patent right

Owner name: FRED HUTCHINSON CANCER RESEARCH CENTRE

Free format text: FORMER OWNER: IKARIA RESEARCH INC.

Effective date: 20140331

C14 Grant of patent or utility model
C41 Transfer of patent application or patent right or utility model
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: Washington, USA

Applicant after: Yigeli Asia Research Co.

Address before: Washington, USA

Applicant before: Ikaria, Inc.

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: IKARIA INC. TO: IKARIA RESEARCH INC.

GR01 Patent grant
TA01 Transfer of patent application right

Effective date of registration: 20140331

Address after: Washington, USA

Applicant after: FRED HUTCHINSON CANCER RESEARCH CENTER

Address before: Washington, USA

Applicant before: Yigeli Asia Research Co.

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1132905

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140423

Termination date: 20191005